These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing. Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785 [TBL] [Abstract][Full Text] [Related]
5. [Comparison of the methods for detecting NTRK gene fusion variations in papillary thyroid carcinoma]. Jiang YY; Chen H; Xu BL; Wang S Zhonghua Bing Li Xue Za Zhi; 2022 Aug; 51(8):726-732. PubMed ID: 35922162 [No Abstract] [Full Text] [Related]
6. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937 [TBL] [Abstract][Full Text] [Related]
7. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467 [TBL] [Abstract][Full Text] [Related]
8. NTRK Fusion in a Cohort of BRAF p. V600E Wild-Type Papillary Thyroid Carcinomas. Lee SE; Lee MS; Bang H; Kim MY; Choi YL; Oh YL Mod Pathol; 2023 Aug; 36(8):100180. PubMed ID: 37003481 [TBL] [Abstract][Full Text] [Related]
9. Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland. Zhang W; Schmitz AA; Kallionpää RE; Perälä M; Pitkänen N; Tukiainen M; Alanne E; Jöhrens K; Schulze-Rath R; Farahmand B; Zong J Acta Oncol; 2024 Jul; 63():542-551. PubMed ID: 38967220 [TBL] [Abstract][Full Text] [Related]
10. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population. Zhao R; Yao F; Xiang C; Zhao J; Shang Z; Guo L; Ding W; Ma S; Yu A; Shao J; Zhu L; Han Y J Pathol Clin Res; 2021 Jul; 7(4):375-384. PubMed ID: 33768710 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer. Dyrbekk APH; Warsame AA; Suhrke P; Ludahl MO; Zecic N; Moe JO; Lund-Iversen M; Brustugun OT Clin Exp Med; 2024 Jan; 24(1):10. PubMed ID: 38240952 [TBL] [Abstract][Full Text] [Related]
12. Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort. Dong K; Yin L; Wang Y; Jia L; Diao X; Huang X; Zhou L; Lin D; Sun Y Hum Pathol; 2024 Jun; 148():87-92. PubMed ID: 38653403 [TBL] [Abstract][Full Text] [Related]
13. Molecular and Cytogenetic Features of NTRK Fusions Enriched in BRAF and RET Double-Negative Papillary Thyroid Cancer. Wu S; Liu Y; Li K; Liang Z; Zeng X J Mol Diagn; 2023 Aug; 25(8):569-582. PubMed ID: 37236546 [TBL] [Abstract][Full Text] [Related]
14. Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients With NTRK Fusion Cancer. Conde E; Hernandez S; Sanchez E; Regojo RM; Camacho C; Alonso M; Martinez R; Lopez-Rios F Arch Pathol Lab Med; 2021 Aug; 145(8):1031-1040. PubMed ID: 33112951 [TBL] [Abstract][Full Text] [Related]
16. How Sensitive is Pan-TRK Immunohistochemistry for Detecting NTRK Fusions in Papillary Thyroid Carcinoma? Hang JF; Lee YC Mod Pathol; 2023 Jul; 36(7):100222. PubMed ID: 37336120 [No Abstract] [Full Text] [Related]
17. Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan. Nakata E; Osone T; Ogawa T; Taguchi T; Hattori K; Kohsaka S Cancer Med; 2024 Jun; 13(12):e7351. PubMed ID: 38925616 [TBL] [Abstract][Full Text] [Related]
18. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing. Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853 [TBL] [Abstract][Full Text] [Related]
19. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955 [TBL] [Abstract][Full Text] [Related]
20. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD; Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]